AstraZeneca bags another US indication for Ultomiris with IgAN approval
AstraZeneca has notched another indication to the belt of its rare disease therapy Ultomiris (ravulizumab) through an accelerated US approval…
22 Oct 2026
Astellas and AI Proteins sign miniprotein therapeutics deal
AI Proteins has signed a research collaboration and licence agreement with Astellas Pharma’s affiliate Astellas Innovation Management for discovering and developing miniprotein therapeutics. Under the deal, AI Proteins is set…
22 Oct 2026
MSD’s Keytruda and Padcev combination receives EC approval
The European Commission (EC) has approved Merck & Co’s (MSD) Keytruda (pembrolizumab) plus Padcev (enfortumab vedotin-ejfv) as perioperative treatment for resectable muscle-invasive bladder cancer (MIBC) in adults. The clearance permits…
21 Oct 2026
FDA approves GSK’s Hibsago as first functional cure for hepatitis B
The US Food and Drug Administration (FDA) has approved GSK’s Hibsago (bepirovirsen), marking the first functional cure available to hepatitis B patients in the US. The drug will be available…
21 Oct 2026
AbbVie races into F1 as pharma companies continue push into sport
AbbVie has continued its recent foray into sport by striking a partnership with Formula 1 (F1) team McLaren, reflecting a growing trend by the pharmaceutical industry to increase visibility via…
21 Oct 2026
FDA approves Cosette’s Evoxac oral solution for Sjögren’s disease
The US Food and Drug Administration (FDA) has granted approval for Cosette Pharmaceuticals’ Evoxac oral solution to treat dry mouth symptoms in adults diagnosed with Sjögren’s disease. The regulatory decision…
21 Oct 2026
MHRA revokes approval for Valneva’s Ixchiq due to safety frailties
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has revoked approval for Valneva’s chikungunya vaccine after deciding that the jab’s risks outweigh its benefits in preventing the tropical disease.…